Biotech Values

[mcbio]

biomaven any comment on today mrk starting rida with mk-0752 the notch inhibitor and mk2206?????

if nothing else mrk is moving forward for sure on combo's

Where was this disclosed? It's not in the ARIA PR and was not mentioned in the ARIA CC and I don't see anything from MRK.

Separately, from the ARIA CC today, it was disclosed that MRK has stopped the Phase 2 trials of rida in advanced prostate cancer patients and KRAS-positive NSCLC patients due to tolerability issues (mouth sores) and a less than adequate response, respectively.

On a positive note, as it pertains to ponatinib, Harvey said that ARIA does expect to ultimately expand ponatinib into AML and MM and, further down the road, solid tumors.